Medigen Vaccine Biologics Receivables

Medigen Vaccine Biologics (6547.TWO) currently reports a receivables of $130M as of June 2026. That compares with $170M in the prior-year period — down 23.7% year over year. Use the charts on this page to explore Medigen Vaccine Biologics's receivables history and peer comparisons.

Medigen Vaccine Biologics's receivables decreased from $170M to $130M — a 23.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Medigen Vaccine Biologics reported $130M in receivables as of June 2026. That compares with $170M in the prior-year period — down 23.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Medigen Vaccine Biologics, and consider following 6547.TWO for alerts when major investors trade the stock.

Medigen Vaccine Biologics is classified in the Healthcare sector. On receivables, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6547.TWO with unrelated industries.